CytoDyn Inc. (CYDY) Form 424B3 — May 20, 2026
CytoDyn Inc. filed a prospectus supplement registering up to 278 million shares of common stock for resale by selling stockholders, including shares underlying warrants. The company will not receive proceeds from these sales, but the registration creates a significant overhang on the ~1.37 billion shares currently outstanding. The filing highlights severe financial distress, noting that auditors have issued a going concern opinion due to substantial doubt about the company's ability to continue operations.
Key figures
- Total Debt
- 29300000
- Cash Position
- 11600000
- Offering Price
- 0.35
- Shares Offered
- 278076375
- Shares Outstanding
- 1369733680
- Accumulated Deficit
- 920600000
- Warrant Exercise Price Low
- 0.2153
- Warrant Exercise Price High
- 0.26
- Potential Proceeds From Warrants
- 23900000
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.